Despina Pantelidou

Dr. Despina Pantelidou


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Michael D. DiamantidisMichael D. Diamantidis
Michael D. Diamantidis
GIGeorgia Ikonomou
Georgia Ikonomou
Ioanna ArgyrakouliIoanna Argyrakouli
Ioanna Argyrakouli
DPDespina Pantelidou
Despina Pantelidou
SDSophia Delicou
Sophia Delicou
Hemoglobinopathies, namely β-thalassemia and sickle cell disease (SCD), are hereditary diseases, characterized by molecular genetic aberrations in the beta chains of hemoglobin. These defects affect the normal production of hemoglobin with severe anemia due to less or no amount of beta globins in patients with β-thalassemia (quantitative disorder), while SCD is a serious disease in which a mutated form of hemoglobin distorts the red blood cells into a crescent shape at low oxygen levels (qualitative disorder). Despite the revolutionary progress in recent years with the approval of gene therapy and gene editing for specific patients, there is an unmet need for highlighting the mechanisms influencing hemoglobin production and for the development of novel drugs and targeted therapies. The identification of the transcription factors and other genetic modifiers of hemoglobin expression is of utmost importance for discovering novel therapeutic approaches for patients with hemoglobinopathies. The aim of this review is to describe these complex molecular mechanisms and pathways affecting hemoglobin expression and to highlight the relevant investigational approaches or pharmaceutical interventions focusing on restoring the hemoglobin normal function by linking the molecular background of the disease with the clinical perspective. All the associated drugs increasing the hemoglobin expression in patients with hemoglobinopathies, along with gene therapy and gene editing, are also discussed.
1

23 March 2004 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
DPDespina Pantelidou
Despina Pantelidou
CTC. Tsatalas
C. Tsatalas
DMD. Margaritis
D. Margaritis
AKAnastasios J Karayiannakis
Anastasios J Karayiannakis
VKV. Kaloutsi
V. Kaloutsi
GBG. Bourikas
G. Bourikas

22 February 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
PKPhilippos Klonizakis
Philippos Klonizakis
NRNoemi Roy
Noemi Roy
IPIoanna Papatsouma
Ioanna Papatsouma
MMMaria Mainou
Maria Mainou
ICIoanna Christodoulou
Ioanna Christodoulou
EVEFTHYMIA VLACHAKI
EFTHYMIA VLACHAKI
The assessment of health-related quality of life (HRQoL) in thalassemia offers a holistic approach to the disease and facilitates better communication between physicians and patients. This study aimed to evaluate the HRQoL of transfusion-dependent thalassemia (TDT) patients in Greece. This was a multicentric, cross-sectional study conducted in 2017 involving 283 adult TDT patients. All participants completed a set of two QoL questionnaires, the generic SF-36v2 and the disease-specific TranQol. Demographic and clinical characteristics were used to predefine patient subgroups. Significant factors identified in the univariate analysis were entered into a multivariate analysis to assess their effect on HRQoL. The SF-36 scores of TDT patients were consistently lower compared to the general population in Greece. The mean summary score of TranQol was relatively high (71 ± 14%), exceeding levels observed in national surveys in other countries. Employment emerged as the most significant independent factor associated with better HRQoL, whereas age had the most significant negative effect. This study represents the first comprehensive QoL assessment of a representative sample of the TDT population in Greece. The implementation of TranQol allowed for the quantification of HRQoL in Greece, establishing a baseline for future follow-up, and identifying more vulnerable patient subgroups.
1

6 January 2006 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
DPDespina Pantelidou
Despina Pantelidou
CTC. Tsatalas
C. Tsatalas
DMD. Margaritis
D. Margaritis
AAA. G. Anastasiadis
A. G. Anastasiadis
VKV. Kaloutsi
V. Kaloutsi
GBG. Bourikas
G. Bourikas

22 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
MVMaria Vlachou
Maria Vlachou
VKVasileios Kamperidis
Vasileios Kamperidis
EVEFTHYMIA VLACHAKI
EFTHYMIA VLACHAKI
GTGeorgios Tziatzios
Georgios Tziatzios
DPDespina Pantelidou
Despina Pantelidou
HKHaralambos Karvounis
Haralambos Karvounis
Patients with beta-thalassemia major (β-ΤΜ) may develop cardiac arrhythmias through a multifactorial mechanism. The current study evaluated the association of cardiac structure and function on echocardiography with atrial ectopic burden on 24-hour tape recording in β-ΤΜ patients. This prospective study included consecutive β-ΤΜ patients. Demographic, laboratory, echocardiographic, cardiac magnetic resonance (CMR) T2* and 24-hour tape recording data were prospectively collected. The patients were classified according to the median value of premature atrial contractions (PACs) on 24-hour tape. In total, 50 β-TM patients (37.6 ± 9.1 years old, 50% male) were divided in 2 groups; PACs ≤ 24/day and > 24/day. Patients with PACs > 24/day were treated with blood transfusion for a longer period of time (39.0 ± 8.6 vs. 32.0 ± 8.9 years, p < 0.007), compared to their counterparts. Older age (OR: 1.121, 95% CI: 1.032–1.217, p = 0.007), longer duration of blood transfusion (OR:1.101, 95% CI:1.019–1.188, p = 0.014), larger LV end-diastolic diameter (OR: 4.522, 95% CI:1.009–20.280, p = 0.049), higher values of LA peak systolic strain (OR: 0.869, 95% CI: 0.783–0.964, p = 0.008), higher MV E/E′ average (OR: 1.407, 95% CI: 1.028–1.926, p = 0.033) and higher right ventricular systolic pressure (OR: 1.147, 95% CI: 1.039–1.266, p = 0.006) were univariably associated with PACs > 24/day. LA peak systolic strain remained significantly associated with PACs > 24/day after adjusting for the duration of blood transfusions or for CMR T2*. The multivariable model including blood transfusion duration and LA peak systolic strain was the most closely associated with PACs > 24/day. Receiver operating characteristic curve analysis identified a left atrial peak systolic strain of 31.5%, as the best cut-off value (83% sensitivity, 68% specificity) for prediction of PACs > 24/day. In β-TM patients, LA peak systolic strain was associated with the atrial arrhythmia burden independently to the duration of blood transfusions and CMR T2*.

21 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
PKPhilippos Klonizakis
Philippos Klonizakis
NRNoemi Roy
Noemi Roy
IPIoanna Papatsouma
Ioanna Papatsouma
MMMaria Mainou
Maria Mainou
ICIoanna Christodoulou
Ioanna Christodoulou
EVEFTHYMIA VLACHAKI
EFTHYMIA VLACHAKI
The assessment of Health-Related Quality of Life (HRQoL) in Thalassemia offers a holistic approach to the disease and facilitates better communication between physicians and patients. This study aimed to evaluate the HRQoL of Transfusion-Dependent Thalassemia (TDT) patients in Greece. This was a multicentre, cross-sectional study conducted in 2017, involving 283 adult TDT patients. All participants completed a set of two QoL questionnaires, the generic SF-36v2 and the disease-specific TranQol. Demographic and clinical characteristics were used to predefine patient subgroups. Significant factors identified in univariate analysis were entered into a multivariate analysis to assess their effect on HRQoL. The SF-36 scores of TDT patients were consistently lower, compared to the general population in Greece. The mean summary score of TranQol was relatively high (71±14%), exceeding levels observed in national surveys in other countries. Employment emerged as the most significant independent factor associated with better HRQoL, whereas age had the most significant negative effect. This study represents the first comprehensive QoL assessment in a representative sample of the TDT population in Greece. The implementation of TranQol allowed for the quantification of HRQoL in Greece, establishing a baseline for future follow-up, and identifying more vulnerable patient subgroups.
1